Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study

Liu, Z; Alexander, JL; Le, K; Zhou, X; Ibraheim, H; Anandabaskaran, S; Saifuddin, A; Lin, KW; McFarlane, LR; Constable, L; Seoane, RC; Anand, N; Bewshea, C; Nice, R; D'Mello, A; Jones, GR; Balarajah, S; Fiorentino, F; Sebastian, S; Irving, PM; Hicks, LC; Williams, HR; Kent, AJ; Linger, R; Parkes, M; Kok, K; Patel, KV; Teare, JP; Altmann, DM; Boyton, RJ; Hart, AL; Lees, CW; Goodhand, JR; Kennedy, NA; Pollock, KM; Ahmad, T; Powell, N

Journal article

Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study

Abstract:: Background

Patients with inflammatory bowel disease (IBD) receiving anti-TNF and JAK-inhibitor therapy have attenuated responses to COVID-19 vaccination. We aimed to determine how IBD treatments affect neutralising antibody responses against the Omicron BA.4/5 variant.

Methods

In this multicentre cohort study, we prospectively recruited 340 adults (69 healthy controls and 271 IBD) at nine UK hospitals between May 28, 2021...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Liu, Z., Alexander, J. L., Le, K., Zhou, X., Ibraheim, H., Anandabaskaran, S., Saifuddin, A., Lin, K. W., McFarlane, L. R., Constable, L., Seoane, R. C., Anand, N., Bewshea, C., Nice, R., D'Mello, A., Jones, G. R., Balarajah, S., Fiorentino, F., Sebastian, S., … Powell, N. (2023). Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study. EClinicalMedicine, 64.

MLA Style

Liu, Z., et al. “Neutralising Antibody Responses against SARS-CoV-2 Omicron BA.4/5 and Wild-Type Virus in Patients with Inflammatory Bowel Disease Following Three Doses of COVID-19 Vaccine (VIP): a Prospective, Multicentre, Cohort Study.” EClinicalMedicine, vol. 64, Elsevier, 2023.

Chicago Style

Liu, Z, JL Alexander, K Le, X Zhou, H Ibraheim, S Anandabaskaran, A Saifuddin, et al. 2023. “Neutralising Antibody Responses against SARS-CoV-2 Omicron BA.4/5 and Wild-Type Virus in Patients with Inflammatory Bowel Disease Following Three Doses of COVID-19 Vaccine (VIP): a Prospective, Multicentre, Cohort Study.” EClinicalMedicine 64.
Share
Print